Mesenchymal stem cells are a topic of intense investigation and subject to several clinical trials, including by Osiris Therapeutics who are currently in Phase III for treatment of graft versus host disease.
This is one of the older patents on mesenchymal stem cells that teaches the differentiation of mesenchymal stem cells into bone forming cells. This is performed through the use of several agents including hydroxyapatite and tricalcium phosphate as carriers of the cells.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.